Healthcare

Report by Horizon Insights

China's laparoscopic robots sector looks set to benefit from policy updates and hospital procurement. With over 180 certificates expected by mid-2024, tender volumes could double, offering significant growth potential. Domestic manufacturers, including MedBot, are gaining market share with second-generation devices narrowing the gap in stability and cost. Toumai, a product of MedBot with government support and competitive pricing, presents a strong alternative to Intuitive Surgical’s da Vinci system which currently boasts c.90% market share.

Technology

Report by Aequitas Research

Pre-IPO research - Medbot is looking to raise around US$1bn in its HK listing. It designs, develops and commercialises surgical robots. The company is pre-revenue but its flagship products are near the registration approval stage. Globally, Intuitive Surgical with a M/Cap of US$100bn+, dominates the market. Intuitive’s products are the industry standard but are expensive which might allow Medbot to penetrate. It is a subsidiary of MicroPort, which will make it easier for it to enter hospitals.